We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron Surges on Coronavirus Treatment Development Efforts
Read MoreHide Full Article
Shares of biotech major Regeneron Pharmaceuticals (REGN - Free Report) have surged 49% in the year so far compared with the industry’s growth of 2.4%.
Price has rallied particularly from the onset of the year as Regeneron is one of the leading biotech companies along with Gilead Sciences, Inc. (GILD - Free Report) and Moderna Inc. (MRNA - Free Report) , among others, that is working on antibodies and vaccines for the treatment of COVID-19.
Regeneron’s investigational two-antibody "cocktail" for the treatment and prevention of COVID-19 shows promise and investors are banking on the successful development of the candidate as it will generate a new stream of revenues for the company, given the widespread outbreak. The company recently announced encouraging first data from a descriptive analysis of a phase I/II/III trial of REGN-COV2, which showed that the candidate reduced viral load and the time to alleviate symptoms in non-hospitalized patients suffering from COVID-19. REGN-COV2 also showed positive trends in reducing medical visits.
In addition, REGN-COV2 is currently being studied in a phase II/III clinical study for the treatment of COVID-19 in hospitalized patients, the phase III open-label RECOVERY study of hospitalized patients in the U.K. and a phase III study for the prevention of COVID-19 in household contacts of infected individuals.
Meanwhile, Regeneron has signed an agreement with the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) and the U.S. Department of Defense, whereby the company was awarded a $450-million contract to manufacture and supply filled and finished REGN-COV2 to the U.S. government.
Further, Regeneron has collaborated with Swiss pharma giant Roche (RHHBY - Free Report) to develop, manufacture and distribute REGN-COV2, whereby the former will distribute REGN-COV2 in the United States and the latter will be responsible for distribution outside the country, thereby increasing the geographical reach of the cocktail treatment.
Apart from this, Regeneron’s efforts to expand the label of its approved drugs and concurrently develop the pipeline are impressive. Dupixent continues to maintain momentum for the company, even though lead drug Eylea’s sales have been affected by the ongoing pandemic. The company has a solid and diverse portfolio, which will reap returns for the company even after REGN-COV2 loses steam once the vaccines come out. Libtayo too is off to a solid start and sales should pick up further on label expansions of the drug.
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
With users in 180 countries and soaring revenues, it’s set to thrive on remote working long after the pandemic ends. No wonder it recently offered a stunning $600 million stock buy-back plan.
The sky’s the limit for this emerging tech giant. And the earlier you get in, the greater your potential gain.
Image: Bigstock
Regeneron Surges on Coronavirus Treatment Development Efforts
Shares of biotech major Regeneron Pharmaceuticals (REGN - Free Report) have surged 49% in the year so far compared with the industry’s growth of 2.4%.
![](https://staticx-tuner.zacks.com/images/zadmin_tuner_image/regn_2020_01_10(1).jpg)
Price has rallied particularly from the onset of the year as Regeneron is one of the leading biotech companies along with Gilead Sciences, Inc. (GILD - Free Report) and Moderna Inc. (MRNA - Free Report) , among others, that is working on antibodies and vaccines for the treatment of COVID-19.
Regeneron’s investigational two-antibody "cocktail" for the treatment and prevention of COVID-19 shows promise and investors are banking on the successful development of the candidate as it will generate a new stream of revenues for the company, given the widespread outbreak. The company recently announced encouraging first data from a descriptive analysis of a phase I/II/III trial of REGN-COV2, which showed that the candidate reduced viral load and the time to alleviate symptoms in non-hospitalized patients suffering from COVID-19. REGN-COV2 also showed positive trends in reducing medical visits.
In addition, REGN-COV2 is currently being studied in a phase II/III clinical study for the treatment of COVID-19 in hospitalized patients, the phase III open-label RECOVERY study of hospitalized patients in the U.K. and a phase III study for the prevention of COVID-19 in household contacts of infected individuals.
Meanwhile, Regeneron has signed an agreement with the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) and the U.S. Department of Defense, whereby the company was awarded a $450-million contract to manufacture and supply filled and finished REGN-COV2 to the U.S. government.
Further, Regeneron has collaborated with Swiss pharma giant Roche (RHHBY - Free Report) to develop, manufacture and distribute REGN-COV2, whereby the former will distribute REGN-COV2 in the United States and the latter will be responsible for distribution outside the country, thereby increasing the geographical reach of the cocktail treatment.
Apart from this, Regeneron’s efforts to expand the label of its approved drugs and concurrently develop the pipeline are impressive. Dupixent continues to maintain momentum for the company, even though lead drug Eylea’s sales have been affected by the ongoing pandemic. The company has a solid and diverse portfolio, which will reap returns for the company even after REGN-COV2 loses steam once the vaccines come out. Libtayo too is off to a solid start and sales should pick up further on label expansions of the drug.
Regeneron currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks’ Single Best Pick to Double
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
With users in 180 countries and soaring revenues, it’s set to thrive on remote working long after the pandemic ends. No wonder it recently offered a stunning $600 million stock buy-back plan.
The sky’s the limit for this emerging tech giant. And the earlier you get in, the greater your potential gain.
Click Here, See It Free >>